JP5386508B2 - インドリル−ピリドン誘導体類 - Google Patents

インドリル−ピリドン誘導体類 Download PDF

Info

Publication number
JP5386508B2
JP5386508B2 JP2010543556A JP2010543556A JP5386508B2 JP 5386508 B2 JP5386508 B2 JP 5386508B2 JP 2010543556 A JP2010543556 A JP 2010543556A JP 2010543556 A JP2010543556 A JP 2010543556A JP 5386508 B2 JP5386508 B2 JP 5386508B2
Authority
JP
Japan
Prior art keywords
title compound
carboxylic acid
oxo
dihydro
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010543556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510055A5 (enExample
JP2011510055A (ja
Inventor
ストークス，スティーブン
フォロップ，ニコラ
フィウマーナ，アンドレア
ドライスデール，マーティン
ベッドフォード，サイモン
ウェッブ，ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0801090.2A external-priority patent/GB0801090D0/en
Priority claimed from GBGB0818695.9A external-priority patent/GB0818695D0/en
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of JP2011510055A publication Critical patent/JP2011510055A/ja
Publication of JP2011510055A5 publication Critical patent/JP2011510055A5/ja
Application granted granted Critical
Publication of JP5386508B2 publication Critical patent/JP5386508B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010543556A 2008-01-22 2009-01-20 インドリル−ピリドン誘導体類 Expired - Fee Related JP5386508B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0801090.2A GB0801090D0 (en) 2008-01-22 2008-01-22 New chemical compounds
GB0801090.2 2008-01-22
GBGB0818695.9A GB0818695D0 (en) 2008-10-11 2008-10-11 New chemical compounds
GB0818695.9 2008-10-11
PCT/GB2009/000149 WO2009093012A1 (en) 2008-01-22 2009-01-20 Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity

Publications (3)

Publication Number Publication Date
JP2011510055A JP2011510055A (ja) 2011-03-31
JP2011510055A5 JP2011510055A5 (enExample) 2012-03-01
JP5386508B2 true JP5386508B2 (ja) 2014-01-15

Family

ID=40377594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010543556A Expired - Fee Related JP5386508B2 (ja) 2008-01-22 2009-01-20 インドリル−ピリドン誘導体類

Country Status (17)

Country Link
US (5) US8916591B2 (enExample)
EP (1) EP2294065B1 (enExample)
JP (1) JP5386508B2 (enExample)
CN (1) CN101970424B (enExample)
AU (1) AU2009207478B2 (enExample)
BR (1) BRPI0906495B8 (enExample)
CA (1) CA2712959C (enExample)
DK (1) DK2294065T3 (enExample)
EA (1) EA021464B1 (enExample)
ES (1) ES2461799T3 (enExample)
IL (1) IL206808A (enExample)
MX (1) MX2010007525A (enExample)
NZ (1) NZ586756A (enExample)
PL (1) PL2294065T3 (enExample)
PT (1) PT2294065E (enExample)
WO (1) WO2009093012A1 (enExample)
ZA (1) ZA201005210B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5386508B2 (ja) 2008-01-22 2014-01-15 ヴァーナリス アールアンドディー リミテッド インドリル−ピリドン誘導体類
GB0912499D0 (en) * 2009-07-18 2009-08-26 Vernalis R&D Ltd Indopyl-pyridone derivatives
CA2794801C (en) 2010-04-07 2019-01-15 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2760857A1 (en) 2011-09-27 2014-08-06 F.Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
CN107406417B (zh) * 2015-01-28 2020-06-09 拜耳制药股份公司 4H-吡咯并[3,2-c]吡啶-4-酮衍生物
WO2019126081A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
JP2021532181A (ja) * 2018-07-24 2021-11-25 エピザイム，インク． Ｓｍａｒｃａ２アンタゴニストとして有用なピリジン−２−オン化合物
US10280721B1 (en) 2018-07-27 2019-05-07 Upwing Energy, LLC Artificial lift
US10370947B1 (en) * 2018-07-27 2019-08-06 Upwing Energy, LLC Artificial lift
US10787873B2 (en) 2018-07-27 2020-09-29 Upwing Energy, LLC Recirculation isolator for artificial lift and method of use
US10253606B1 (en) 2018-07-27 2019-04-09 Upwing Energy, LLC Artificial lift
PT3842425T (pt) * 2018-08-24 2024-07-02 Transthera Sciences Nanjing Inc Novo inibidor derivado de quinolina
US11686161B2 (en) 2018-12-28 2023-06-27 Upwing Energy, Inc. System and method of transferring power within a wellbore
CN112625027B (zh) * 2019-09-24 2022-09-09 药捷安康(南京)科技股份有限公司 杂环衍生物及其用途
EP4543455A4 (en) * 2022-06-24 2026-06-03 Enalare Therapeutics Inc METHODS OF TREATMENT FOR NEUROLOGICAL VENTILATORY FAILURE
CN115594634B (zh) * 2022-10-26 2024-10-01 浙江工业大学 一种连续化制备4-硝基吡唑的新工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2442428A1 (en) * 2001-03-28 2002-10-10 Mark D. Wittman Novel tyrosine kinase inhibitors
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
AU2004251175A1 (en) 2003-06-05 2005-01-06 Merck & Co., Inc. Substituted indoles and a process for preparing substituted indoles
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CA2600914A1 (en) * 2005-01-28 2007-07-26 Mark E. Fraley Inhibitors of checkpoint kinases
EP1891048A1 (en) * 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
JP2009543770A (ja) * 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
JP5386508B2 (ja) 2008-01-22 2014-01-15 ヴァーナリス アールアンドディー リミテッド インドリル−ピリドン誘導体類
AU2010247412A1 (en) * 2009-05-15 2011-11-24 Novartis Ag 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or CYP11B1

Also Published As

Publication number Publication date
EP2294065A1 (en) 2011-03-16
US20150099736A1 (en) 2015-04-09
CA2712959C (en) 2015-06-23
CA2712959A1 (en) 2009-07-30
MX2010007525A (es) 2010-08-18
CN101970424B (zh) 2013-06-12
BRPI0906495B1 (pt) 2020-11-10
IL206808A0 (en) 2010-12-30
US10696652B2 (en) 2020-06-30
NZ586756A (en) 2012-04-27
ES2461799T3 (es) 2014-05-21
US20200361905A1 (en) 2020-11-19
US20180244652A1 (en) 2018-08-30
EA201001197A1 (ru) 2011-04-29
JP2011510055A (ja) 2011-03-31
US20110021498A1 (en) 2011-01-27
BRPI0906495A8 (pt) 2015-10-06
IL206808A (en) 2015-08-31
US8916591B2 (en) 2014-12-23
ZA201005210B (en) 2011-03-30
EP2294065B1 (en) 2014-03-19
PT2294065E (pt) 2014-05-15
EA021464B1 (ru) 2015-06-30
DK2294065T3 (da) 2014-04-28
AU2009207478B2 (en) 2013-11-21
CN101970424A (zh) 2011-02-09
BRPI0906495B8 (pt) 2021-05-25
BRPI0906495A2 (pt) 2015-07-14
PL2294065T3 (pl) 2014-11-28
AU2009207478A1 (en) 2009-07-30
US20170298043A1 (en) 2017-10-19
WO2009093012A1 (en) 2009-07-30
US9604975B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
JP2011510055A (ja) インドリル−ピリドン誘導体類
CN106170288B (zh) 药物化合物
CN114761086A (zh) 作为parp7抑制剂的哒嗪酮
CN115697990A (zh) 基于吲唑的化合物和相关使用方法
KR101985050B1 (ko) 피라진카르복사미드 화합물
CN102471314B (zh) 适合于特别是睡眠障碍和药物成瘾的治疗的螺氨基化合物
KR20230173234A (ko) 인다졸계 화합물 및 관련된 사용 방법
TW202322811A (zh) Parp-1降解劑及其用途
KR20120097410A (ko) 베타－트립타제 억제제로서의 인돌릴－피페리디닐 벤질아민
WO2022166974A1 (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN113968856A (zh) 一类具有激酶抑制活性的化合物
WO2024151638A2 (en) Compounds for fgfrs inhibitors
CN120835881A (zh) 能够降解雄激素受体的双官能化合物
EP3083597B1 (en) Fluoromethyl-substituted pyrrole carboxamides as cav2.2 calcium channel blockers
CN116917279A (zh) Btk抑制剂
CN100436445C (zh) 吡唑衍生物
CN117430589A (zh) 2-氨基嘧啶类化合物或其盐及其制备方法和用途
WO2025034912A9 (en) Compounds for fgfr inhibition
WO2011010083A1 (en) Indolyl-pyridone derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131007

R150 Certificate of patent or registration of utility model

Ref document number: 5386508

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees